Pfizer (NYSE:PFE) Trading Down 3.2% - What's Next?

Pfizer Inc. (NYSE:PFE - Get Free Report) shares traded down 3.2% during trading on Friday . The stock traded as low as $23.20 and last traded at $23.52. 22,906,284 shares were traded during trading, a decline of 42% from the average session volume of 39,257,020 shares. The stock had previously closed at $24.29.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on PFE. Bank of America reissued a "neutral" rating and issued a $29.00 price objective on shares of Pfizer in a research report on Tuesday, December 10th. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Truist Financial decreased their price target on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a report on Wednesday, December 18th. UBS Group dropped their price objective on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a report on Wednesday, January 8th. Finally, Citigroup restated a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, Pfizer currently has a consensus rating of "Moderate Buy" and an average target price of $31.92.

Pfizer Stock Down 5.4 %

The business has a 50 day moving average price of $25.87 and a 200 day moving average price of $26.74. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The stock has a market cap of $130.39 billion, a PE ratio of 16.31, a P/E/G ratio of 0.64 and a beta of 0.67.

Remove Ads

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping analysts' consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion for the quarter, compared to analysts' expectations of $17.26 billion. During the same quarter last year, the company earned $0.10 EPS. The business's revenue was up 24.7% on a year-over-year basis. Equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Insider Buying and Selling at Pfizer

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of the company's stock in a transaction on Thursday, February 13th. The shares were bought at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the acquisition, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.06% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Pfizer

Several institutional investors and hedge funds have recently added to or reduced their stakes in PFE. Exeter Financial LLC increased its stake in shares of Pfizer by 88.5% during the first quarter. Exeter Financial LLC now owns 28,195 shares of the biopharmaceutical company's stock worth $714,000 after purchasing an additional 13,239 shares in the last quarter. Quent Capital LLC boosted its stake in Pfizer by 15.1% during the first quarter. Quent Capital LLC now owns 12,878 shares of the biopharmaceutical company's stock worth $326,000 after buying an additional 1,694 shares during the last quarter. Legacy Private Trust Co. grew its holdings in shares of Pfizer by 4.4% in the first quarter. Legacy Private Trust Co. now owns 14,366 shares of the biopharmaceutical company's stock valued at $364,000 after purchasing an additional 600 shares during the period. Central Pacific Bank Trust Division increased its holdings in shares of Pfizer by 19.4% during the 1st quarter. Central Pacific Bank Trust Division now owns 21,634 shares of the biopharmaceutical company's stock worth $548,000 after buying an additional 3,516 shares during the last quarter. Finally, Versant Capital Management Inc increased its position in shares of Pfizer by 186.0% during the 1st quarter. Versant Capital Management Inc now owns 19,446 shares of the biopharmaceutical company's stock worth $493,000 after purchasing an additional 12,647 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.